Table 2.

Analysis between average survival time (months) and clinicopathological features in 424 cases of lung adenocarcinoma

Clinicopathological	Univariate analysis			Multivariate analysis
Features	Survival time (SE)	95%CI	P	Exp (B)	95%CI	P
Age (years)
≤60	38.0 (1.94)	(34.2, 41.8)	0.054	0.625	(0.501, 0.872)	0.003*
>60	31.5 (2.10)	(27.4, 35.6)
Gender
Female	39.7 (2.11)	(35.5, 43.8)	0.001*	0.645	(0.445, 0.940)	0.022*
Male	30.6 (1.95)	(26.8, 34.4)
Smoking status
Smoker	29.8 (2.30)	(25.3, 34.3)	0.014*	0.743	(0.527, 1.098)	0.144
Nonsmoker	37.8 (1.85)	(34.2, 41.4)
Pathological degree
Well and moderated differentiation	39.6 (1.69)	(36.2, 42.9)	0.000*	0.534	(0.392, 0.700)	0.000*
Poor differentiation	20.1 (2.06)	(16.1, 24.1)
Clinical stages
I+II+III	46.5 (2.04)	(42.5, 50.5)	0.000*	0.475	(0.192, 0.368)	0.000*
IV	24.8 (1.73)	(21.4, 28.2)
EGFR mutation
Positive	42.2 (2.04)	(38.2, 46.2)	0.000*	0.415	(0.288, 0.529)	0.000*
Negative	26.3 (1.95)	(22.5, 30.1)

Note: *P<0.05.

Abbreviations: SE, standard error; 95% CI, 95% confidence interval.